Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Front Immunol. 2023 Jun 16;14:1204363. doi: 10.3389/fimmu.2023.1204363. eCollection 2023.
CD8 T cell exhaustion is a stable dysfunctional state driven by chronic antigen stimulation in the tumor microenvironment (TME). Differentiation of exhausted CD8 T cells (CD8 TEXs) is accompanied by extensive transcriptional, epigenetic and metabolic reprogramming. CD8 TEXs are mainly characterized by impaired proliferative and cytotoxic capacity as well as the increased expression of multiple co-inhibitory receptors. Preclinical tumor studies and clinical cohorts have demonstrated that T cell exhaustion is firmly associated with poor clinical outcomes in a variety of cancers. More importantly, CD8 TEXs are regarded as the main responder to immune checkpoint blockade (ICB). However, to date, a large number of cancer patients have failed to achieve durable responses after ICB. Therefore, improving CD8 TEXs may be a breakthrough point to reverse the current dilemma of cancer immunotherapy and eliminate cancers. Strategies to reinvigorate CD8 TEXs in TME mainly include ICB, transcription factor-based therapy, epigenetic therapy, metabolism-based therapy and cytokine therapy, which target on different aspects of exhaustion progression. Each of them has its advantages and application scope. In this review, we mainly focus on the major advances of current strategies to reinvigorate CD8 TEXs in TME. We summarize their efficacy and mechanisms, identify the promising monotherapy and combined therapy and propose suggestions to enhance the treatment efficacy to significantly boost anti-tumor immunity and achieve better clinical outcomes.
CD8 T 细胞耗竭是肿瘤微环境(TME)中慢性抗原刺激驱动的一种稳定的功能失调状态。耗竭的 CD8 T 细胞(CD8 TEX)的分化伴随着广泛的转录、表观遗传和代谢重编程。CD8 TEX 的主要特征是增殖和细胞毒性能力受损,以及多种共抑制受体的表达增加。临床前肿瘤研究和临床队列研究表明,T 细胞耗竭与多种癌症的不良临床结局密切相关。更重要的是,CD8 TEX 被认为是免疫检查点阻断(ICB)的主要反应者。然而,迄今为止,大量癌症患者在接受 ICB 后未能获得持久反应。因此,改善 CD8 TEX 可能是扭转当前癌症免疫治疗困境和消除癌症的突破点。在 TME 中重新激活 CD8 TEX 的策略主要包括 ICB、基于转录因子的治疗、表观遗传治疗、基于代谢的治疗和细胞因子治疗,它们针对耗竭进展的不同方面。它们各自都有其优点和应用范围。在这篇综述中,我们主要关注当前重新激活 TME 中 CD8 TEX 的策略的主要进展。我们总结了它们的疗效和机制,确定了有前途的单一疗法和联合疗法,并提出了增强治疗效果的建议,以显著增强抗肿瘤免疫并获得更好的临床结果。